Fresenius Medical Care Q3 2026: Big EPS Beat, Guarded CEO, Trimmed Outlook
As seen on the 24/7 Wall St. homepage on November 3, 2026.
An adjusted EPS beat of this size usually gets celebrated, but new CEO Shervin Korangy called management "muted in our assessment of performance" and narrowed full-year operating income guidance to the lower half of the prior range on fourth-quarter headwinds. Operating income fell 23% as the China exit and transformation costs hit reported numbers.
Continue ReadingShow less
Fresenius Medical Care posted adjusted earnings per share of $1.24 for the third quarter of 2026, beating expectations, with revenue growth of just 1.1% weighed down by divestitures and a deliberate pullback in China.
The company discontinued local production of the 4008A hemodialysis system and exited the peritoneal dialysis business in China, driving reported operating income down 23% year over year and pushing the Care Enablement segment to a reported operating loss.
New CEO Shervin Korangy, three weeks into the role, described management as "muted in our assessment of performance" and framed the business as still at an early stage of development in many areas. Restraint from a new chief executive lowers the bar for future quarters.
Sponsored
The company narrowed its full-year 2026 operating income outlook to the lower half of its prior range, now between flat and a negative mid-single-digit percent decline at constant currency, citing anticipated fourth-quarter headwinds. Operating cash flow rose 7.6% year over year, and the FME25+ program keeps its EUR 1.2 billion cumulative savings target by end-2027 intact.
The 5008X CAREsystem rollout reached roughly 16% of U.S. machines by quarter end, and the company launched the multiFiltratePRO acute kidney injury system in the U.S. in October, its first FDA-cleared system for regional citrate anticoagulation using the Ci-Ca Protocol. These milestones give the bull case something to point to even as guidance disappointed.